<DOC>
	<DOC>NCT00766025</DOC>
	<brief_summary>The main purpose of this study is to examine Taiwanese subjects identified as CYP2C19 poor and extensive metabolizers while taking single and multiple dosing a rosuvastatin calcium.</brief_summary>
	<brief_title>Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin</brief_title>
	<detailed_description />
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Subject must have blood drawn for genotyping (determination of EM or PM of CYP2C19, determination of OATPC1B1, BCRP 421C&gt;A, and CYP2C9. Males and females aged 2065, inclusive Women who are surgically sterilized, postmenopausal for at least one year, or not pregnant and/or lactating. Women of childbearing potential must be willing to abstain from sexual activity or use an effective contraception as outlined in protocol. Subjects with deoxyribonucleic acid (DNA) that codes for OATPC 1B1 *5 and *15, BCRP 421C&gt;A and/or non wildtype CYP2C9 History of adverse drug reaction or hypersensitivity to statins or drugs with a similar chemical structure to rosuvastatin History or presence of gastrointestinal, hepatic, or renal disease or other conditions known to interfere with absorption, distribution, metabolism and excretion (ADME) of drugs Any contraindication determined by review of a detailed medical and drug history, complete physical examination, vital signs, blood chemistry, hematology, and electrocardiogram (ECG)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Taiwanese Subjects</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>Poor Metabolizers</keyword>
	<keyword>Extensive Metabolizers</keyword>
	<keyword>Taiwanese Subjects identified as CYP2C19 Poor or Extensive Metabolizers</keyword>
</DOC>